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To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myeloﬁbrosis
(MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia
(AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity
conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-ﬂudarabine-
cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of
neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and
event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and
platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%,edgments on page 1846.
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M. Robin et al. / Biol Blood Marrow Transplant 20 (2014) 1841e18681842P ¼ .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In
conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF,
especially using RIC TCF-based regimens, deserves further investigation to improve results.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is currently the only curative option for patients with
primary myeloﬁbrosis (PMF) and myeloﬁbrosis secondary to
polycythemia vera or essential thrombocythemia (SMF).
Several studies have shown survival rates of 40% to 60% after
HSCT [1e5]. Transplant-related mortality (TRM) remains
relatively high (10% to 40%) pursuant to inherent features of
the underlying disease, such as its presentation commonly at
an advanced age. HSCT is therefore usually reserved for the
minority of younger higher risk patients [1e5].
The use of reduced-intensity conditioning (RIC) in pa-
tients with myeloﬁbrosis (MF) has been explored, showing
its applicability in older patients [6e9]. Umbilical cord blood
transplantation (UCBT) is a valid alternative for patients
lacking an HLA-matched donor [10,11] and double UCBT has
extended this procedure to adults [12]. In a previous report,
Takagi et al. [13] showed engraftment in 13 patients and a
4-year overall survival (OS) of 28% after RIC UCBT in 14
patients with hematological malignancies associated with
bone marrow ﬁbrosis, including 1 case of PMF and 1 of SMF.
Another recent study compared outcomes of unrelated UCBT
with other related and unrelated hematopoietic stem cell
sources in patients with PMF given myeloablative (MAC) or
nonmyeloablative conditioning. Lower neutrophil engraft-
ment and higher TRM were reported after UCBT. The type of
stem cell source did not appear to have an impact on OS (36%
at 2 years), although the small number of UCBTs (N ¼ 11) did
not allow for deﬁnitive conclusions in this trial [14]. In this
retrospective registry-based analysis, we describe UCBT
outcomes in a series of patients with PMF or SMF.METHODS
Data were retrieved from the Eurocord database and supplemented
using the EBMT registry; a questionnairewas sent to the centers to complete
missing data and to conﬁrm the diagnosis. Neutrophil recovery was deﬁned
as an absolute neutrophil count .5  109/L for 3 consecutive days and
platelet recovery as a platelet count 20  109/L for 7 consecutive days
without transfusion support. Graft failure (GF) was deﬁned as never having
reached neutrophils .5  109/L within the ﬁrst 60 days after UCBT or
documentation of autologous reconstitution by chimerism analysis. MAC
was deﬁned as a regimen containing either total body irradiation (TBI) with
a dose 6 Gy, a dose of oral busulfan >8 mg/kg or, a dose of intravenous
busulfan >6.4 mg/kg.
The Kaplan-Meier method was used to estimate OS and event free
survival (EFS), considering GF, relapse, and death as events. Cumulative
incidence was performed to estimate neutrophil and platelet recovery,
relapse, and TRM. Considering the small number of patients, multivariate
analysis was not performed. Statistical analysis was processed on SPSS
version 19 (SPSS Inc., Chicago, IL) and S-Plus (MathSoft) software packages
(Insightful Corp., Seattle, WA).
All patients provided informed consent for data treatment, according to
the Declaration of Helsinki. This study was approved by the International
Review Board of Eurocord and CMWP-EBMT.
Thirty-ﬁve patients with PMF (n¼ 20) or SMF (n¼ 15) who underwent a
double (n¼ 22) or single (n ¼ 13) UCBT between 2005 and 2012 in 23 EBMT
centers were reported to Eurocord. Seven cases (3 PMF and 4 SMF) had
transformed into acute myeloid leukemia (AML) at the time of UCBT: 4 were
transplanted in complete remission. Patient, disease, and transplant char-
acteristics are shown in Table 1.
Themedian age at UCBTwas 54 years (range, 28 to 63). Themedian time
from diagnosis of MF to UCBT was 27 months for PMF (range, 5 to 150) and10 months for SMF (range, 1.4 to 111). The median time from AML diagnosis
to UCBT was 6 months (range, .1 to 99). Fifteen patients (43%) underwent
splenectomy before UCBT, and the median time from splenectomy to
transplantation was 8 months (range, 2 to 206). Eleven patients (31%)
received a MAC regimen and 24 (69%) a RIC. Themost common conditioning
regimen was TBI associated with cyclophosphamide and ﬂudarabine (TCF,
n¼ 17): of these, 4 patients received TCF with a myeloablative TBI dose of 12
Gy and 13 had a RIC with low-dose TBI 2 Gy. Cord blood units were 5/6 and
4/6 HLA matched to the recipient in 23% and 77% of the cases, respectively.
Graft-versus-host disease (GVHD) prophylaxis was calcineurin inhibitor
based for 34 patients (97%), givenwith mycophenolate mofetil in 19 of those
patients (54%).RESULTS
Hematological Recovery
Neutrophil recovery was achieved in 28 patients at a
median time of 30 days (range, 11 to 60), whereas 19 had
platelet recovery at a median time of 42 days (range, 13 to
91). Cumulative incidences of day 60 neutrophil recovery and
day 100 platelet recovery were 80% (Figure 1A) and 54%,
respectively. Among patients who achieved neutrophil re-
covery, 20 had evidence of full-donor or mixed chimerism
(data missing for 1 patient). Overall, 14 patients experienced
GF, and 4 of them received a subsequent HSCT (Table 1).
Twelve-month survival was similar in patients with or
without GF (48% versus 52%), whereas patients who did not
achieve neutrophil recovery had poorer survival (14%).
Indeed, some patients lived several years with autologous
reconstitution and active disease (Table 1). According to the
conditioning regimen, 8 of 11 MAC and 20 of 24 RIC achieved
neutrophil recovery. Platelet recovery was achieved in 4MAC
and 15 RIC and was higher in patients who underwent
splenectomy before UCBT (40% versus 70%, P ¼ .02). Impor-
tantly, all patients receiving TCF as conditioning achieved
both neutrophil and platelet recovery. Cell dose, disease
characteristics, age, or cytomegalovirus serostatus had no
signiﬁcant impact on engraftment.Graft-versus-Host Disease
Ten patients developed grades II to IV acute GVHD (7
grade II, 2 grade III, 1 grade IV) with a median time of onset of
33 days (range, 14 to 94). Among 18 patients at risk for
chronic GVHD, 6 developed limited and 1 extensive chronic
GVHD, with a median onset time of 167 days (range, 91
to 328).Disease Status
Overall, 15 patients experienced progressive disease or
relapse at a median of 7 months (range, 1 to 31) after UCBT: 3
were originally diagnosed with AML (in ﬁrst complete
remission at UCBT), 6 with PMF, and 6 with SMF (Table 1).
Among patients with relapse, 7 had GF. One patient with
AML relapsed 2.5 years after UCBT and received a second
allogeneic HSCT from a matched unrelated donor, dying of
veno-occlusive disease 92 days later. Among 11 patients alive
at least 6 months after UCBT without relapse, 3 had available
marrow biopsy results: 1 had complete resolution of marrow
ﬁbrosis (grade 0 at 21 months), 1 regressed from grade III to I
Table 1
Patients, Disease and Transplant Characteristics, and Causes of Death
Gender
and Age
Diagnosis
JAK2-V617 F
Mutation
Prognostic
Scores: Lille at
Diagnosis [16]
DIPSS at UCBT [17]
Splenectomy
Degree of BM
Fibrosis*
Time from
Diagnosis
of MF to
UCBT (mo)
Type of Graft TNC
(107)/CD34 (105)/kg
at Collection
Conditioning
Regimen
Recovery Delay (d):
Neutrophils/Platelets
Chimerism
State Main Cause of Death Follow-
up
from
UCBT (d)
1 Male
31
PMF
-
Low
High
Yes
Severe
27 Single CB
2.8/.22
RIC: other
ATG
21/35
unknown
Dead MF 137
2 Female
51
PMF
-
High
High
Yes
Severe
27 Single CB
3.94/.91
MAC: other -/-
not done
Dead Septic shock after infusion
of autologous HSC
34
3 Female
58
ET SMF
-
Intermediate
High
Yes
Moderate
7 Single CB
4.63/1.39
RIC: TCF
ATG
25/37
mixed
Dead Cerebral hemorrhage 147
4 Male
52
ET SMF
mutated
Intermediate
Intermediate-2
No
Severe
1 Double CB
6.38/1.55
RIC: other
ATG
-/-
autologous reconstitution
Dead MF continuous progression
even after a second UCBT
performed for rejection
140
5 Male
27
ET SMF
mutated
Low
Low
Yes
-
7 Double CB
3.58/-
MAC: TCF 27/34
full donor
Dead MF 1480
6 Male
59
PMF
mutated
High
-
Yes
Moderate
29 Double CB
4.3/1.87
MAC: TCF 35/90
full donor
Alive in Remission 1592
7 Male
47
PMF
wild type
High
Intermediate-2
No
Mild
5 Double CB
5.7/2.19
RIC: TCF 41/69
full donor
Alive in Remission 1321
8 Female
36
PMF
wild type
Intermediate
Intermediate-1
No
Severe
82 Single CB
3.3/.56
MAC: other 44/-
autologous reconstitution
Alive with MF 2198
9 Male
62
PMF
-
Intermediate
-
No
-
10 Double CB
3.54/2.01
RIC: other -/-
not done
Dead Infection þ ARDS 21
10 Male
51
PMF
-
Low
Low
Yes
Severe
41 Double CB
6.04/2.69
MAC: other
ATG
21/19
autologous reconstitution
Dead Bacterial infection 2074
11 Male
49
PMF
-
Intermediate
-
Yes
Severe
13 Double CB
3.75/1.28
RIC: TCF 37/85
full donor
Dead MF 1072
12 Male
61
MPN/MDS SMF
mutated
Intermediate
Intermediate-2
No
Moderate
10 Double CB
4.15/1.32
RIC: TCF 60/91
full donor
Dead EBV-related PTLD 284
13 Male
54
ET SMF
-
Intermediate
Intermediate-1
No
Moderate
8 Single CB
3.4/1.5
RIC: other
ATG
31/-
full donor
Dead MF 83
14 Male
54
ET SMF
wild type
-
Intermediate-1
No
Severe
30 Single CB
3.97/2.32
RIC: other
ATG
28/-
full donor
Dead Acute GVHD 61
15 Male
37
PMF
mutated
Intermediate
Intermediate-2
Yes
Severe
12 Double CB
4.75/1.46
RIC: other
ATG
36/42
autologous reconstitution
Dead MF 400
16 Female
63
PMF
wild type
Low
Intermediate-2
Yes
-
150 Double CB
4.41/.79
RIC: TCF 17/17
mixed
Alive in Remission 1083
17 Male
56
PV SMF
mutated
High
Intermediate-2
Yes
Moderate
4 Single CB
4.72/3.71
RIC: TCF 10/13
autologous reconstitution
Dead MF 1969
18 Female
43
ET SMF
mutated
Intermediate
Intermediate-2
Yes
-
23 Double CB
4.79/1.5
RIC: TCF
ATG
11/18
mixed
Alive with MF 1855
19 Male
57
PMF
wild type
-
Intermediate-2
Yes
-
79 Double CB
4.37/1.89
RIC: TCF
ATG
51/-
mixed
Dead EBV-related PTLD 77
20 Female
54
PMF
mutated
Low
High
Yes
-
85 Double CB
5.41/-
RIC: TCF 33/62
mixed
Dead MF 351
21 Male
60
ET SMF
wild type
Low
Intermediate-1
Yes
Severe
111 Double CB
5.06/1.56
RIC: other
ATG
23/-
full donor
Dead Pulmonary infection 118
22 Female
38
PMF
-
Intermediate
-
No
Severe
20 Double CB
-/-
RIC: other
ATG
36/50
autologous reconstitution
Alive with MF 658
23 Male
58
PMF
wild type
High
High
No
Severe
7 Double CB
8.58/4.76
MAC: TCF 30/-
mixed
Alive in remission 702
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Table 1
(continued )
Gender
and Age
Diagnosis
JAK2-V617 F
Mutation
Prognostic
Scores: Lille at
Diagnosis [16]
DIPSS at UCBT [17]
Splenectomy
Degree of BM
Fibrosis*
Time from
Diagnosis
of MF to
UCBT (mo)
Type of Graft TNC
(107)/CD34 (105)/kg
at Collection
Conditioning
Regimen
Recovery Delay (d):
Neutrophils/Platelets
Chimerism
State Main Cause of Death Follow-
up
from
UCBT (d)
24 Male
54
PMF
wild type
Intermediate
High
No
Mild
12 Single CB
4.54/2.65
RIC: other
ATG
-/-
autologous reconstitution
Dead Infection 53
25 Female
56
PV SMF
mutated
-
High
Yes
-
26 Double CB
6.76/2.03
RIC: other
ATG
-/-
autologous reconstitution
Dead MOF after a second UCBT
performed for rejection
233
26 Female
51
PMF
wild type
High
Intermediate-2
No
Moderate
14 Single CB
-/-
MAC: other
ATG
-/-
autologous reconstitution
Alive in remission after
a second HSCT (MUD)
performed for rejection
413
27 Female
58
ET SMF
wild type
Low
Intermediate-2
No
Moderate
7 Double CB
5.92/3.73
RIC: TCF 35/55
autologous reconstitution
Alive with MF 192
28 Female
49
PMF
wild type
High
Intermediate-1
No
Moderate
28 Single CB
5.25/3
RIC: other
ATG
16/62
full donor
Dead Infection 126
29 Male
40
ET SMF>>AML
-
Low
NE
No
Severe
63 Single CB
1.74/.23
MAC: other
ATG
30/30
full donor
Dead VOD after a second HSCT
(MUD) performed for AML
relapse
1073
30 Male
58
PMF>>AML
mutated
-
NE
No
-
51 Double CB
4.24/.84
MAC: TCF 17/-
autologous reconstitution
Dead AML 60
31 Female
58
PV SMF>>AML
mutated
Low
NE
No
Severe
11 Double CB
4.26/1.66
RIC: TCF 20/38
mixed
Alive in remission 651
32 Male
42
PMF>>AML
mutated
High
NE
No
Severe
29 Double CB
6.83/2.26
RIC: TCF 37/-
full donor
Dead ARDS 144
33 Male
44
ET SMF>>AML
wild type
High
NE
No
-
104 Single CB
3.63/1.34
MAC: other
ATG
31/-
full donor
Dead AML 445
34 Male
60
ET SMF>>AML
wild type
Low
NE
No
-
8 Double CB
4.32/2.18
MAC: other
ATG
-/-
autologous reconstitution
Dead Acute GVHD after a second
UCBT performed for rejection
213
35 Female
60
PMF>>AML
wild type
High
NE
No
Moderate
5 Single CB
4.92/2.03
RIC: TCF 22/48
full donor
Alive in remission 206
DIPSS indicates dynamic international prognostic scoring system; TNC, total nucleated cells; BM, bone marrow; CB, cord blood; ATG, antithymoglobulin; ET, essential thrombocythemia; MPN/MDS, myeloproliferative/mye-
lodysplastic syndrome; ARDS, acute respiratory distress syndrome; EBV, Epstein-Barr virus; PTLD, post-transplant lymphoproliferative disease; PV, polycythemia vera; MOF, multiorgan failure; MUD, matched unrelated donor;
NE, not assessable; VOD, veno-occlusive disease.
* According to the European Consensus on Grading Bone Marrow Fibrosis (2005) [18].
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Figure 1. Outcome of patients with MF after UCBT. (A) Cumulative incidence of neutrophil recovery (60-day ¼ 80%, n ¼ 28). (B) Probability of OS (2-year ¼ 44%,
n ¼ 16). (C) Probability of EFS (2-year ¼ 30%, n ¼ 10). (D) Probability of EFS in the RIC population (n ¼ 24) according to the conditioning regimen (d, TCF; . . . ., others:
2-year ¼ 44% versus 0%, P ¼ .001).
M. Robin et al. / Biol Blood Marrow Transplant 20 (2014) 1841e1868 1845(after 12 months), and 1 regressed from grade II to I (after 9
months).
TRM, OS, and EFS
Overall, 24 patients died: 10 of relapse and 14 of
transplant-related causes, detailed in Table 1. The median
follow-up was 24 months (range, 6 to 73). The cumulative
incidence of TRM at 2 years was 35%. The 2-year OS and EFS
rates were 44% and 30%, respectively (Figure 1B,C). In uni-
variate analysis, age, time from diagnosis to transplantation,
number of cord blood units infused, cell dose, and disease
characteristics had no signiﬁcant impact on EFS or OS.
According to diagnosis, EFS was 35% for PMF, 18% for SMF,
and 36% for AML. Among the 24 patients given RIC, those
who received TCF (n¼ 13) had a signiﬁcantly higher EFS (44%
versus 0%, P ¼ .001; Figure 1D), whereas in patients receiving
MAC, no signiﬁcant difference was found according to the
type of conditioning regimen used.
DISCUSSION
In this study we describe patients receiving UCBT for PMF
or SMF. We selected our cases from the Eurocord registry, a
large international registry for UCBT, to which only 35 cases
were reported from 23 centers over an 8-year period, con-
ﬁrming that UCBT is rarely performed in patients with MF.
These patients were at high risk at UCBT because of the
advanced disease stage (20% had MF in blast phase). The
median age at UCBT was relatively high, similar to that
reported in patients having received a graft from an adult
unrelated donor. In our series GF was a major concern. Thelower engraftment rate could be explained by the association
of the underlying disease and the stem cell source, which are
both well-known independent risk factors for delayed
engraftment and GF. Nevertheless, 2 observations can be
highlighted in our population: patients who experienced GF
but achieved neutrophil recovery had prolonged survival,
and patients who received a TCF-based conditioning had
an excellent engraftment. Importantly, 13 of 17 patients
receiving TCF had a RIC regimen, which may have contrib-
uted to the improved results in this advanced-age population
in terms of both engraftment and EFS.
In our results patients who never achieved neutrophil
recovery had poorer survival. Onemay argue that this ﬁnding
may be correlated with the type of conditioning used.
Unfortunately, in our study we were unable to explore this
ﬁnding further because we were dealing with small sub-
groups of patients. No other prognostic factors were identi-
ﬁed, including cell dose. However, it is important to note that
32 of 33 assessable patients received an adequate dose of
total nucleated cells (2.5  107/kg).
As previously described in other HSCT settings, we
demonstrated that it is possible to obtain regression of bone
marrow ﬁbrosis after UCBT. Furthermore, some patients had
long-term survival, despite particularly adverse prognostic
features (age, advanced disease stage), and we observed
encouraging results for cases of leukemic transformation
that would otherwise have an expected survival of 4 months
in the absence of HSCT [15].
The role of JAK2 inhibitors in the MF treatment pathway
has yet to be determined. In our study only 1 patient with
M. Robin et al. / Biol Blood Marrow Transplant 20 (2014) 1841e18681846PMF was treated with JAK2 inhibitors before UCBT. There-
fore, we were not able to draw any conclusion in this speciﬁc
setting.
In conclusion, our results suggest that UCBT is feasible
for patients with MF. However, the interpretation of these
results was limited by the small sample size and the retro-
spective registry-based nature of the study; therefore, larger
trials are needed to identify speciﬁc risk factors. The selection
of cord blood units with higher numbers of cells or the use of
double-UCBT, associated with a TCF-based RIC regimen,
should be further explored to improve outcomes in this
particular subset of patients.ACKNOWLEDGMENTS
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